title: Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy.
abstract: BACKGROUND
  Surgical resection has been the treatment of choice for hepatocellular carcinoma (HCC), but the resection rate remains low in cirrhotic patients and recurrence is common. Unfavorable results compared with benign disease and the shortage of organ donors have led to a restricted indication for orthotopic liver transplantation (OLT) for HCC.
  
  
  METHODS
  The aim of this study was to analyze the results of our surgical approach to HCC in patients with cirrhosis. The first treatment strategy indicated in these patients was OLT. From January 1990 to May 1999, 85 patients underwent OLT and the remaining 35 had surgical resection.
  
  
  RESULTS
  One-, 3-, and 5-year survival rates were 84%, 74%, and 60% versus 83%, 57%, and 51%, respectively, in the OLT and resection groups (p = 0.34). Hepatic tumor recurrence was much less frequent in the OLT group than in the resection group. The 1-, 3-, and 5-year disease-free survival rates were 83%, 72%, and 60% versus 70%, 44%, and 31%, respectively (p = 0.027). In the multivariate Cox regression analysis, macroscopic vascular invasion was the only factor independently associated with death or recurrence after OLT (p = 0.006). After partial liver resection, the tumors significantly associated with mortality and recurrence in the multivariate analysis were solitary or multiple tumors greater than 2cm with microscopic vascular invasion (pathologic pT3) (p = 0.01).
  
  
  CONCLUSIONS
  Our results confirm that in cirrhotic patients, OLT may provide better outcomes than liver resection in carefully selected HCC and that longterm survival is similar to the results of OLT in cirrhotic patients without tumors.
authors.affiliation: Liver Transplant Unit, Ciutat Sanitaria Universitaria Bellvitge, University of Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Figueras
authors.forename: E
authors.initials: E
authors.lastname: Jaurrieta
authors.forename: C
authors.initials: C
authors.lastname: Valls
authors.forename: E
authors.initials: E
authors.lastname: Ramos
authors.forename: T
authors.initials: T
authors.lastname: Serrano
authors.forename: A
authors.initials: A
authors.lastname: Rafecas
authors.forename: J
authors.initials: J
authors.lastname: Fabregat
authors.forename: J
authors.initials: J
authors.lastname: Torras
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D000075202:Contraindications; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy / Q000706:statistics & numerical data; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D008113:Liver Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D016031:Liver Transplantation / Q000379:methods / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012086:Reoperation / Q000706:statistics & numerical data; D012306:Risk; D016896:Treatment Outcome